A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
TEMPO is an interventional cohort study recruiting injecting drug users attending needle and
syringe programs (NSP) in Australia. Three hundred participants will be invited to on-site
HCV testing with NSP integrated care for HCV treatment.
Participants will be screened for HCV using point-of-care testing and HCV positive
participants will be offered treatment with Sofosbuvir/Velpatasvir. Of those who initiate
treatment, participants will receive weekly peer-based support on-treatment and return at End
of Treatment (ETR) and 12 weeks following end of treatment (SVR12) for clinical follow-up.